Pause on Gardasil China sales from Feb to at least mid-2025 Keytruda beats, Gardasil misses Q4 sales estimates Merck pulls Gardasil's long-term sales target Shares tumble 11% in early trading Feb ...

The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is halting shipments to the world’s second-most populous country.

The drugmaker plans to temporarily pause shipments of its Gardasil vaccine to China at least through the middle of the year. Chairman and CEO Robert Davis told analysts the pause will help pare ...

The company said that sales range reflects a decision to halt shipments of Gardasil, a vaccine that prevents cancer from HPV, into China beginning in February and going through at least mid-2025.

Merck reported a decline of 17% in sales of Gardasil to $1.55 billion, a vaccine that prevents cancer from HPV, the most common sexually transmitted infection in the U.S., primarily due to lower ...

Merck MRK-0.87%decrease; red down pointing triangle shares tumbled more than 11% Tuesday morning after the drugmaker gave 2025 revenue guidance that fell short of analyst expectations and said it ...

Quarterly Gardasil sales of $1.55 billion missed Wall Street's estimates of around $1.8 billion, which has been pared back nearly 20% since the issues in China were disclosed last summer.

Merck 2025 Sales Forecast Underwhelms as It Pauses Gardasil Sales in China Shares of Merck slid Tuesday after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales forecast due ...